Chief Executive Officer
R. Nolan Townsend has served as LEXEO Therapeutics Chief Executive Officer and member of the Board of Directors since the start of LEXEO’s substantive business operations in January 2020. Prior to LEXEO, Mr. Townsend held roles of increasing responsibility at Pfizer Inc including in positions as President, Pfizer Rare Disease for the North America region and President, Pfizer Rare Disease for International developed markets; responsible for overseeing overall strategy, the cross functional organization and operating budget in those businesses.
Mr. Townsend has over a decade of experience with Pfizer, first joining the company in Corporate Finance and subsequently in roles of increasing responsibility across Corporate Finance, Corporate Strategy, Operations, Marketing, General Management and Commercial leadership in Pfizer’s New York headquarters, Asia, Africa/Middle East and Europe. Prior to Pfizer, Mr. Townsend worked in the healthcare investment banking group at Lehman Brothers, advising healthcare companies on strategic financing transactions and mergers and acquisitions.
Mr. Townsend currently serves on New York City’s Life Sciences Advisory Board and received his Master’s in Business Administration from the Harvard Business School and his Bachelor of Arts in Economics from the University of Pennsylvania.